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BACKGROUND
In patients with diabetes, hospitalization can complicate the achievement of recom-
mended glycemic targets. There is increasing evidence that a closed-loop delivery 
system (artificial pancreas) can improve glucose control in patients with type 1 diabe-
tes. We wanted to investigate whether a closed-loop system could also improve glyce-
mic control in patients with type 2 diabetes who were receiving noncritical care.
METHODS
In this randomized, open-label trial conducted on general wards in two tertiary hos-
pitals located in the United Kingdom and Switzerland, we assigned 136 adults with 
type 2 diabetes who required subcutaneous insulin therapy to receive either closed-
loop insulin delivery (70 patients) or conventional subcutaneous insulin therapy, 
according to local clinical practice (66 patients). The primary end point was the 
percentage of time that the sensor glucose measurement was within the target range 
of 100 to 180 mg per deciliter (5.6 to 10.0 mmol per liter) for up to 15 days or until 
hospital discharge.
RESULTS
The mean (±SD) percentage of time that the sensor glucose measurement was in 
the target range was 65.8±16.8% in the closed-loop group and 41.5±16.9% in the 
control group, a difference of 24.3±2.9 percentage points (95% confidence interval 
[CI], 18.6 to 30.0; P<0.001); values above the target range were found in 23.6±16.6% 
and 49.5±22.8% of the patients, respectively, a difference of 25.9±3.4 percentage 
points (95% CI, 19.2 to 32.7; P<0.001). The mean glucose level was 154 mg per 
deciliter (8.5 mmol per liter) in the closed-loop group and 188 mg per deciliter 
(10.4 mmol per liter) in the control group (P<0.001). There was no significant 
between-group difference in the duration of hypoglycemia (as defined by a sensor 
glucose measurement of <54 mg per deciliter; P = 0.80) or in the amount of insulin 
that was delivered (median dose, 44.4 U and 40.2 U, respectively; P = 0.50). No episode 
of severe hypoglycemia or clinically significant hyperglycemia with ketonemia oc-
curred in either trial group.
CONCLUSIONS
Among inpatients with type 2 diabetes receiving noncritical care, the use of an au-
tomated, closed-loop insulin-delivery system resulted in significantly better glycemic 
control than conventional subcutaneous insulin therapy, without a higher risk of 
hypoglycemia. (Funded by Diabetes UK and others; ClinicalTrials.gov number, 
NCT01774565.)
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The burden of diabetes is increasing worldwide,1 as is the proportion of patients with diabetes in hospitals. More than one 
quarter of hospitalized patients in the United 
States and other developed countries have diabe-
tes.2-4 In such patients, the achievement of recom-
mended glycemic targets5,6 is complicated by vari-
able metabolic responses to acute illness, changes 
in the amounts and timing of dietary intake, nu-
tritional support, and drug-induced temporally 
rapid alterations in insulin sensitivity from medi-
cations such as glucocorticoids.7-9
Strong associations have been reported between 
the rate of hyperglycemia among inpatients and an 
increased length of hospital stay and increased 
rates of complications and death.10,11 Although the 
correction of hyperglycemia diminishes the risk 
of adverse clinical outcomes,12 conventional insu-
lin therapy increases the risk of hypoglycemia, 
which is associated with increased morbidity and 
length of hospital stay.13 The implementation of 
current guidelines for inpatient glycemic man-
agement is hindered by the need for vigilant and 
constant blood glucose monitoring and the ad-
ministration of insulin with meals, which increas-
es the workload of hospital staff members and 
reduces staff adherence.5,6 Consequently, glycemic 
control in hospitalized patients is often inade-
quate,2,14 which has spurred the development of 
more effective and safe management strategies.15
An automated system that delivers insulin in 
response to glucose levels can address this need. 
Closed-loop glucose control (also known as the 
artificial pancreas) consists of a continuous glu-
cose monitor and an insulin pump, coupled with 
a control algorithm that directs insulin delivery 
on the basis of real-time sensor glucose measure-
ments.16 Such autonomous glucose control obvi-
ates the need for the input of hospital staff mem-
bers. There is increasing evidence that closed-loop 
technology improves glucose control in patients 
with type 1 diabetes.17,18 In the critical care set-
ting, closed-loop technology has been evaluated 
for intravenous insulin delivery.19,20 However, for 
staffing and safety reasons, subcutaneous insulin 
delivery has been feasible and pragmatic in pa-
tients receiving noncritical care.21 Here, we report 
the results of a two-center, randomized, open-label 
trial of closed-loop insulin delivery without meal-
associated bolus administration in a diverse co-
hort of patients receiving noncritical care. We 
hypothesized that closed-loop insulin delivery 
would be safe and improve glycemic control with-
out increasing the risk of hypoglycemia.
Me thods
Patients
From August 2, 2016, to December 11, 2017, we 
recruited patients on general wards at the Univer-
sity Hospital in Bern, Switzerland, and at Adden-
brooke’s Hospital in Cambridge, United Kingdom. 
Inclusion criteria included an age of 18 years or 
older and inpatient hyperglycemia requiring sub-
cutaneous insulin therapy. Exclusion criteria were 
type 1 diabetes, pregnancy or breast-feeding, and 
any physical or psychological disease or the use 
of medication that was likely to interfere with 
the conduct of the trial or the interpretation of the 
results. Inpatients were identified through hospital 
electronic records. All the patients provided writ-
ten informed consent before the initiation of trial 
procedures.
Trial Design
We randomly assigned the patients to receive in-
sulin by means of a fully automated, closed-loop 
system (closed-loop group) or conventional sub-
cutaneous therapy (control group). Patients were 
followed for a maximum of 15 days or until hos-
pital discharge. Randomization was performed 
by means of the minimization method with the 
use of Minim randomization software,22 which 
is a biased-coin approach with a probability of 0.7 
to 0.8 for allocation of the “best fitting” treatment. 
Randomization was stratified according to glycat-
ed hemoglobin level, body-mass index (the weight 
in kilograms divided by the square of the height 
in meters), and pretrial total daily insulin dose to 
balance the two groups. Investigators who analyzed 
the trial data were aware of the trial-group assign-
ments.
Trial Procedures
The body weight, height, and total daily insulin 
dose were recorded for each patient after enroll-
ment. Throughout the trial, the patients chose 
standard hospital meals at usual mealtimes, ac-
cording to local practice. The patients were free 
to consume other meals and snacks and were 
unrestricted in their usual activity on the general 
ward. In the two groups, glucose levels were 
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measured with the use of a continuous glucose 
monitor (Freestyle Navigator II, Abbott Diabetes 
Care). A glucose sensor was inserted subcutane-
ously into the abdomen or upper arm by the in-
vestigator and calibrated according to the manu-
facturer’s instructions. Point-of-care capillary 
glucose measurements (StatStrip Glucose Hospi-
tal Meter System, Nova Biomedical, or Accu-Chek 
Inform II, Roche Diagnostics) were performed by 
nursing staff members according to local clinical 
practice in the two trial groups.
Closed-Loop Insulin Delivery
Investigators discontinued each patient’s usual 
insulin therapy and sulfonylurea medication, if 
prescribed, on the day of closed-loop initiation. 
All other medications were continued. The inves-
tigator inserted a subcutaneous cannula into the 
abdomen for delivery of a rapid-acting insulin ana-
logue (Humalog, Eli Lilly, or NovoRapid, Novo 
Nordisk) by means of a trial pump (Dana Diabe-
care R, Sooil). The investigator initialized the con-
trol algorithm by using the patient’s weight and 
pretrial total daily insulin dose. When sensor 
readings became available, the investigator initi-
ated automated closed-loop glucose control, which 
continued for up to 15 days. A low-glucose sensor 
alarm on the continuous glucose-monitoring re-
ceiver was initialized at a threshold of 63 mg per 
deciliter (3.5 mmol per liter).
The automated closed-loop system consisted of 
a model predictive control algorithm (version 
0.3.70) residing on a control algorithm device (Dell 
Latitude 10 Tablet, Dell) linked by a USB cable to 
the continuous glucose-monitoring receiver (Fig. 
S1 in the Supplementary Appendix, available with 
the full text of this article at NEJM.org). The tab-
let device communicated with the pump by means 
of a Bluetooth wireless communication protocol. 
No prandial insulin boluses were delivered, and 
the timing or carbohydrate content of meals was 
not included in the control algorithm. (Additional 
details regarding the closed-loop system are pro-
vided in the Supplementary Appendix.)
At the end of the closed-loop period, patients 
completed a brief questionnaire to evaluate their 
satisfaction and trust of automated glucose con-
trol with the closed-loop system, their acceptance 
of wearing trial devices, and their views as to 
whether they would recommend the technology 
to other patients. Conventional insulin therapy 
and sulfonylurea medication were resumed at the 
end of closed-loop use as appropriate.
Conventional Insulin Therapy
For each patient, the usual insulin and other anti-
hyperglycemic therapies were continued through-
out the trial period. To reflect usual care, the 
continuous glucose monitor was masked to the 
patient, investigators, and hospital staff members. 
Each patient’s glucose control was managed by the 
clinical team, according to local clinical practice 
on the basis of capillary glucose measurements. 
The clinical team was allowed to modify and ad-
just each patient’s insulin and other antihypergly-
cemic therapies and to initiate additional point-of-
care capillary glucose measurements as appropriate.
Trial Oversight
The protocol (available at NEJM.org) was approved 
by the local research ethics committee at each 
center and by regulatory authorities in Switzer-
land (Swissmedic) and in the United Kingdom 
(Medicines and Healthcare Products Regulatory 
Agency). The safety aspects of the trial were over-
seen by an independent data and safety monitor-
ing board. The trial was performed in accordance 
with the principles of the Declaration of Helsinki.
Abbott Diabetes Care supplied discounted con-
tinuous glucose-monitoring devices, sensors, and 
details regarding the communication protocol to 
facilitate real-time connectivity; company repre-
sentatives reviewed the manuscript before sub-
mission but otherwise had no role in the trial 
conduct. All the authors participated in the design 
of the trial or provided patient care and obtained 
samples. The first, second, and last author wrote 
the first draft of the manuscript. The last author 
designed and implemented the control algorithm, 
and all the authors critically reviewed the manu-
script. The first and last authors vouch for the 
completeness and accuracy of the data and analy-
ses and for the adherence of the trial to the proto-
col. All the authors made the decision to submit 
the manuscript for publication.
Primary and Secondary Outcomes
The primary outcome was the percentage of time 
that the sensor glucose measurement was in the 
target glucose range of 100 to 180 mg per deci-
liter (5.6 to 10.0 mmol per liter) for up to 15 days 
or until hospital discharge. Secondary outcomes 
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were the percentage of time that the sensor glu-
cose measurement was either above or below the 
target range; the percentage of time spent above 
360 mg per deciliter (20.0 mmol per liter), below 
70 mg per deciliter (3.9 mmol per liter), below 
54 mg per deciliter (3.0 mmol per liter), and be-
low 50 mg per deciliter (2.8 mmol per liter); the 
area under the curve below 63 mg per deciliter 
(3.5 mmol per liter) and below 54 mg per deciliter; 
the mean daily sensor glucose measurement; and 
the total daily insulin dose. We used data collected 
throughout the trial period to evaluate glucose 
variability according to the standard deviation and 
the coefficient of variation in the sensor glucose 
measurement. We calculated the between-day co-
efficient of variation in the sensor glucose mea-
surement from daily mean glucose values (mid-
night to midnight). Additional secondary outcomes 
and exploratory analyses are described in the Sup-
plementary Appendix.
Safety end points included clinically signifi-
cant hyperglycemia (>360 mg per deciliter) with 
ketonemia and severe hypoglycemia (<40 mg per 
deciliter), as determined by point-of-care capillary 
measurements, along with other adverse events 
and serious adverse events.
Statistical Analysis
The trial was designed to have a power of 80% 
to detect a clinically significant between-group 
difference in the primary outcome of 20 percent-
age points with the use of a two-sided t-test and an 
alpha level of 0.05. To reflect heterogeneity among 
the patients, a standard deviation of ±39 for the 
primary outcome was used for the power calcu-
lations. We planned that 150 patients would un-
dergo randomization in order to permit the analy-
sis of at least 48 hours of data from 120 patients.
The intention-to-treat analysis was performed 
on data collected during subcutaneous insulin 
delivery. Data from patients who participated in 
a separate feasibility study21 were not included in 
the present analysis. Outcomes were calculated 
with the use of GStat software, version 2.2 (Uni-
versity of Cambridge), and statistical analyses were 
performed with the use of SPSS software, version 
21.0 (IBM). We used the unpaired t-test to compare 
normally distributed variables and the Mann–
Whitney U test for highly skewed variables. The 
numbers of events that were related to a capillary 
glucose measurement of less than 63 mg per deci-
liter and 40 mg per deciliter and more than 360 mg 
per deciliter were tabulated in each trial group 
and compared with the use of Fisher’s exact test. 
Values are reported as means (±SD) or medians 
(interquartile range), unless stated otherwise. All 
P values are two-tailed, and P values of less than 
0.05 were considered to indicate statistical sig-
nificance.
R esult s
Patients
Of the 165 patients who were invited to enroll in 
the trial, 138 consented to participate (Fig. S2 in 
the Supplementary Appendix). One patient was 
withdrawn before randomization because of im-
minent hospital discharge. Of the remaining 137 
patients, 70 were assigned to the closed-loop group 
and 67 to the control group. One patient in the 
control group was excluded from the analysis be-
cause the transition from intravenous insulin to 
subcutaneous insulin did not occur as originally 
planned.
The demographic and clinical characteristics 
of the patients were similar with respect to sex, 
age, body-mass index, glycated hemoglobin level, 
duration of diabetes, receipt of insulin, and insulin 
requirements (Table 1). Sepsis was the predomi-
nant reason for admission (in 43% of the patients); 
approximately two thirds of the patients were 
being treated with basal bolus insulin therapy. 
Additional data regarding the patients, including 
reasons for admission and antidiabetic treat-
ment before randomization, are provided in Ta-
bles S1 and S2 in the Supplementary Appendix. 
The burden of coexisting illnesses was signifi-
cantly higher in the closed-loop group than in the 
control group, according to the mean score on the 
Charlson Comorbidity Index (9.4±3.4 vs. 7.0±2.8, 
P<0.001). Scores on this index range from 0 to 
33, with a score of ≥5 indicating a severe burden 
of illness. Additional details are provided in Ta-
ble S3 and Fig. S3 in the Supplementary Appendix.
Overall Glucose Control
The mean (±SD) percentage of time that the sen-
sor glucose measurement was in the target glu-
cose range (primary outcome) was 65.8±16.8% in 
the closed-loop group and 41.5±16.9% in the con-
trol group, for a difference of 24.3±2.9 percentage 
points (95% confidence interval [CI], 18.6 to 30.0; 
The New England Journal of Medicine 
Downloaded from nejm.org at CAMBRIDGE UNIVERSITY LIBRARY on September 24, 2018. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med 379;6 nejm.org August 9, 2018 551
Closed-Loop Insulin Delivery in Noncritical Care
P<0.001) (Table 2). The mean sensor glucose mea-
surement was significantly lower in the closed-
loop group than in the control group (154±29 mg 
per deciliter vs. 188±43 mg per deciliter; differ-
ence, 35±6 mg per deciliter; 95% CI, 23 to 47; 
P<0.001). Values above the target range (>180 mg 
per deciliter) were found in 23.6±16.6% of the pa-
tients in the closed-loop group and in 49.5±22.8% 
of those in the control group, a difference of 
25.9±3.4 percentage points (95% CI, 19.2 to 32.7; 
P<0.001); there was no significant between-group 
difference in the time spent at levels lower than 
the target range (<100 mg per deciliter, P = 0.37) 
or lower than 70 mg per deciliter (P = 0.13). The 
burden of hypoglycemia was similar in the two 
groups, as measured by the area under the curve 
of values below 63 mg per deciliter and below 
54 mg per deciliter (Table 2). There was no signifi-
cant between-group difference in the median total 
daily insulin dose that was delivered (44.4 U in the 
closed-loop group and 40.2 in the control group, 
P = 0.50). The mean glucose variability in individual 
patients, as measured by the standard deviation of 
the sensor glucose value, was significantly lower 
in the closed-loop group than in the control group 
(46 vs. 59, P<0.001) (Table 2). The mean coefficient 
of variation in the sensor glucose measurement 
between 24-hour periods was significantly lower 
in the closed-loop group than in the control group 
(15.6±8.0% vs. 21.7±12.2%, P = 0.001). The 24-hour 
sensor glucose measurements and insulin-deliv-
ery profiles are shown in Figure 1. End points 
for the first 48 hours and for the period thereaf-
ter until the end of the trial are provided in Table 
S4 in the Supplementary Appendix.
Capillary glucose measurements that were ob-
tained before meals and before bedtime were sig-
nificantly lower in the closed-loop group than in 
the control group (P<0.01 for all comparisons) 
(Table 2). Hypoglycemic episodes with a capillary 
glucose measurement of less than 63 mg per deci-
liter, as confirmed by point-of-care measurements, 
occurred three times in the closed-loop group (in 
3 patients) and nine times in the control group 
(in 8 patients). Hospital staff members treated 
these episodes with oral carbohydrates according 
to local guidelines, without the need for intrave-
nous dextrose. As per protocol, two patients in the 
closed-loop group received supplemental insulin 
when their sensor glucose measurements were 
greater than 434 mg per deciliter for more than 
1 hour. Supplemental insulin was not administered 
in the control group, since the sensor glucose mea-
surement was masked in those patients.
Overnight and Daytime Glucose Control
The mean percentage of time that sensor glucose 
measurements were in the target range was higher 
in the closed-loop group than in the control group, 
both overnight (midnight to 8 a.m.) and during 
the daytime (8 a.m. to midnight). Overnight, the 
percentage of time was 74.0±19.3% in the closed-
loop group and 54.2±25.1% in the control group, 
for a difference of 19.8±3.8 percentage points 
(95% CI, 12.2 to 27.4; P<0.001); during the day-
time, the percentage of time was 61.9±18.9% 
and 34.9±18.6%, respectively, for a difference of 
26.9±3.2 percentage points (95% CI, 20.6 to 33.3; 
P<0.001) (Table 3). The sensor glucose measure-
ments were significantly lower in the closed-loop 
group than in the control group, both overnight 
and during the daytime (P<0.001 for both com-
parisons), as were the standard deviations of sen-
sor glucose measurements during overnight pe-
riods (P<0.001) and daytime periods (P = 0.001). In 
addition, the between-night and between-day coef-
ficients of variation in the sensor glucose measure-
ment were significantly lower in the closed-loop 
group than in the control group (P = 0.004 for both 
comparisons). There was no significant between-
group difference in the nocturnal and daytime 
burden of hypoglycemia, as measured by the area 
Characteristic
Closed-Loop Group 
(N = 70)
Control Group 
(N = 66)
Male sex — no. (%) 50 (71) 43 (65)
Age — yr 67.7±10.1 67.1±13.0
Body-mass index† 32.7±8.2 32.3±8.1
Glycated hemoglobin
Percentage 8.1±1.9 8.0±1.9
Mean value — mmol/mol 65±21 64±21
Duration of diabetes — yr 17.1±11.2 15.5±11.2
Duration of insulin therapy — yr 10.0±9.1 8.0±9.1
Total daily insulin dose — U 64.2±59.4 50.6±38.9
*  Plus–minus values are means ±SD. There was no significant difference be-
tween the groups in the listed categories.
†  The body-mass index is the weight in kilograms divided by the square of the 
height in meters.
Table 1. Characteristics of the Patients at Baseline.*
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under the curve for values below 63 mg per deci-
liter (P = 0.86 and P = 0.24, respectively).
Follow-up Period and Patient Feedback
The mean trial follow-up period, which was de-
fined as the period from the first sensor reading 
until the last sensor reading, was 7.9±3.9 days in 
the closed-loop group and 6.4±4.0 days in the 
control group (P = 0.03). This time frame included 
suspension of the trial period in 8 patients in the 
closed-loop group and 3 patients in the control 
group because of surgery or other procedures that 
required transient removal of trial devices. Sensor 
glucose measurements were available during 96% 
of the follow-up period in the closed-loop group 
and 92% of the follow-up period in the control 
group (P = 0.01). The closed-loop system was opera-
tional during 99% of the time when sensor glucose 
measurements were available.
Overall, 54 of 62 patients (87%) in the closed-
loop group reported that they were happy with 
their glucose levels during the trial, and 61 of 62 
(98%) reported that they were happy to have their 
glucose levels controlled automatically by the 
closed-loop system (Fig. S4 in the Supplementary 
Appendix). All 62 patients reported that they would 
Outcome
Closed-Loop Group 
(N = 70)
Control Group 
(N = 66) P Value
Time spent in sensor glucose measurement — %
Within target range of 100 to 180 mg/dl: primary end 
point
65.8±16.8 41.5±16.9 <0.001
Mean >180 mg/dl 23.6±16.6 49.5±22.8 <0.001
Mean >360 mg/dl 1.2±4.8 2.6±7.0 0.18
Mean <100 mg/dl 10.6±6.7 9.0±13.2 0.37
Median <70 mg/dl (IQR) 0.5 (0.0–1.1) 0.0 (0.0–1.8) 0.13
Median <54 mg/dl (IQR) 0.0 (0.0–0.1) 0.0 (0.0–0.0) 0.80
Median <50 mg/dl (IQR) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.79
Glucose — mg/dl 154±29 188±43 <0.001
SD of glucose — mg/dl† 46±19 59±19 <0.001
Coefficient of variation in glucose level — % 29.4±6.4 31.5±9.3 0.13
Between-day coefficient of variation in glucose level — % 15.6±8.0 21.7±12.2 0.001
Median AUC per day for glucose level (IQR)‡
<63 mg/dl  7.0 (0.0–298.7)   0.0 (0.0–305.7) 0.28
<54 mg/dl 0.0 (0.0–17.1) 0.0 (0.0–0.0) 0.63
Median total daily insulin dose (IQR) — U 44.4 (27.2–70.6) 40.2 (26.5–65.5) 0.50
Capillary glucose values — mg/dl§
Before breakfast (5 to 8 a.m.) 134±32 156±58 0.009
Before lunch (11 a.m. to 1 p.m.) 175±49 227±63 <0.001
Before dinner (4 to 7 p.m.) 161±66 195±59 0.002
Before bedtime (9 p.m. to midnight) 170±54 218±81 <0.001
No. of events with capillary glucose <63 mg/dl¶ 3 9 0.09
*  Plus–minus values are means ±SD. To convert the values for glucose to millimoles per liter, multiply by 0.05551. IQR 
denotes interquartile range.
†  This category of SD is an average of the variability of sensor glucose measurements for each patient, rather than the 
variation in the mean glucose values among patients in the trial. The category is included because an increased vari-
ability in glucose measurements has been linked to adverse medical outcomes in individual patients.
‡  The area under the curve (AUC) was calculated as the area below the respective threshold throughout the follow-up 
 period, with normalization to a 24-hour period.
§  Capillary glucose values were recorded in 68 patients in the closed-loop group and 65 patients in the control group.
¶  The listed events occurred in 3 patients in the closed-loop group and in 8 patients in the control group.
Table 2. Primary and Secondary Outcomes.*
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recommend the system to a friend or family mem-
ber during hospitalization.
 Adverse Events and Device Deficiencies
No episodes of severe hypoglycemia or clinically 
significant hyperglycemia with ketonemia oc-
curred in either group. Adverse events that were 
related to trial devices occurred in three patients 
in the closed-loop group and three patients in the 
control group. These events included skin irrita-
tion from sensor adhesive and bruising at cannula 
insertion sites. In the closed-loop group, device 
deficiencies included sensor failures in two pa-
tients and a pump-check error in one patient. The 
results for the safety end points are summarized 
in Table 4.
 Discussion
In this trial involving hospitalized patients with 
type 2 diabetes, those who received insulin with 
a fully automated, closed-loop system had signifi-
cantly better glucose control than those who re-
ceived standard subcutaneous insulin therapy. The 
percentage of time that the sensor glucose mea-
surement was in the target range was signifi-
cantly higher in the closed-loop group than in the 
control group, whereas the duration of hypergly-
cemia, the mean glucose level, and glucose vari-
ability were significantly lower. These values were 
achieved without changing the total daily insulin 
dose and without increasing the risk of hypogly-
cemia.
The advantage of a closed-loop system is the 
finely tuned, instantaneous glucose-responsive 
modulation of insulin delivery, with its continual 
adaptation to changing insulin needs during the 
day and between days. In contrast, conventional 
treatment approaches are less responsive to glu-
cose changes and insulin needs; with tighter glyce-
mic control, such treatments are associated with 
an increased risk of hypoglycemia12,23 and adverse 
medical outcomes.13 The latter is a primary con-
cern for many health care professionals and, we 
speculate, may explain why many practitioners are 
reluctant to encourage tight glucose control.
Other techniques that address inpatient glyce-
mic control include remote monitoring and con-
sultation by a dedicated specialist team,24 as well 
as algorithm-driven, computerized, tablet-based 
insulin-dosing support systems for hospital staff 
members.25 Although glycemic benefits have been 
shown with the use of such systems, input by 
staff members is still required, thereby decreas-
ing usability, given the time constraints of daily 
practice.
Our findings expand the results of a single-
center, randomized feasibility trial that evaluated 
a fully automated, closed-loop system during a 
72-hour period.21 Our trial was conducted at two 
centers in two countries, had a longer follow-up 
Figure 1. Sensor Glucose Measurements and Insulin Delivery.
Panel A shows median sensor glucose measurements during closed-loop 
insulin delivery (solid red line) and conventional subcutaneous insulin therapy 
(solid blue line), with the red and blue shaded areas indicating the inter-
quartile range for each treatment. The values were measured during a 24-
hour period from midnight to midnight. The lower and upper limits of the 
glucose target range of 100 to 180 mg per deciliter (5.6 to 10.0 mmol per 
 liter) are indicated by black horizontal dashed lines. To convert the values 
for glucose to millimoles per liter, multiply by 0.05551. Panel B shows the 
median amount of algorithm-directed insulin delivered during the closed-
loop intervention, with the shaded area indicating the interquartile range.
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period, and had a larger sample size in a consid-
erably more diverse and complex inpatient popu-
lation (including 19 patients who were receiving 
hemodialysis). In addition, patients in the closed-
loop group in our trial did not receive long-acting 
basal insulin, as was the case in the feasibility 
study. In spite of enrolling a more challenging and 
more diverse inpatient population, we found that 
patients in the closed-loop group spent a high-
er percentage of time within the glycemic target 
range than those in the control group (a between-
group difference of 24 percentage points in our 
trial vs. 21 percentage points in the feasibility trial) 
and a lower percentage of time above the glyce-
mic target range (a between-group difference of 
26 percentage points vs. 19 percentage points). The 
observed differences may be attributable to en-
hanced adaptive aspects of the control algorithm 
that we used and the longer trial duration, a hy-
pothesis that is supported by the greater benefit 
accrued beyond 48 hours of closed-loop opera-
tion (Fig. S5 in the Supplementary Appendix).
A strength of our trial is that it addressed the 
unmet need for better glycemic control among 
hospitalized patients with diabetes, an issue that 
affects nearly all areas of in-hospital care, patient 
outcomes, and health care costs. The two-country 
design and sample size allowed for the evaluation 
of the safety and efficacy of closed-loop glycemic 
control over a wide range of disease conditions, 
demographic characteristics, and different health 
care systems.
Our trial also has some limitations. Sensor 
glucose measurements were more available and 
the trial duration was longer in the closed-loop 
group than in the control group. The observed 
imbalance may be attributable to between-group 
differences in the burden of coexisting illnesses 
(which was higher in the closed-loop group than 
in the control group), since the presence of such 
illnesses often increases the need for acute hos-
pital care and may prolong hospitalization.26,27 In 
addition, because the sensor glucose measure-
ments were clinically unavailable in the control 
Outcome
Closed-Loop Group 
(N = 70)
Control Group 
(N = 66) P Value
Overnight period from midnight to 8 a.m.
Time spent with sensor glucose value within target 
range of 100 to 180 mg/dl — %
74.0±19.3 54.2±25.1 <0.001
Mean glucose — mg/dl 129±24 160±49 <0.001
SD of glucose — mg/dl 27±15 38±18 <0.001
Coefficient of variation in glucose level — % 20.7±8.4 24.4±9.6 0.02
Between-night coefficient of variation in glucose 
level — %
16.9±9.0 22.9±13.7 0.004
Median AUC per day below 63 mg/dl (IQR) 0.0 (0.0–39.3) 0.0 (0.0–129.3) 0.86
Median insulin dose (IQR) — U 8.0 (4.5–14.5) ND ND
Daytime period from 8 a.m. to midnight
Time spent with sensor glucose value within target 
range of 100 to 180 mg/dl — %
61.9±18.9 34.9±18.6 <0.001
Mean glucose — mg/dl 165±36 204±46 <0.001
SD of glucose — mg/dl 46±16 57±21 0.001
Coefficient of variation in glucose level — % 27.6±5. 5 28.6±10.4 0.48
Between-day coefficient of variation in glucose level 
— %
14.9±8.0 20.7±14.2 0.004
Median AUC per day below 63 mg/dl 0.0 (0.0–71.7) 0.0 (0.0–0.5) 0.24
Median insulin dose (IQR) — U 36.2 (23.0–52.9) ND ND
*  Plus–minus values are means ±SD. ND denotes that the analysis was not done, because the use of long-acting insulin 
in the control group did not allow for the quantification of overnight and daytime insulin doses.
Table 3. Daytime and Overnight Secondary Outcomes.*
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group, any loss of connectivity between the sen-
sor and the receiver device was not detected and 
may have contributed to the collection of fewer 
sensor glucose data in the control group.
As part of the translation of research regard-
ing the closed-loop system into clinical practice, 
further work is required to determine practical 
considerations, facilitate ease of use, and assess 
costs. Standardized procedures will be needed to 
ensure the most effective transition from acute 
care to outpatient care.28,29 Before closed-loop sys-
tems can have widespread use, they may need to 
be integrated with electronic-record systems in 
hospitals and with training for health care pro-
fessionals.
In conclusion, in patients with type 2 diabetes 
who were receiving noncritical care, we found that 
the use of a fully automated, closed-loop insulin-
delivery system resulted in better glycemic control 
than standard insulin therapy. In addition, the im-
proved glucose control was achieved without in-
creasing the risk of hypoglycemia in these patients.
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